Literature DB >> 9651537

Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence.

J C Schwartz1, J Diaz, R Bordet, N Griffon, S Perachon, C Pilon, S Ridray, P Sokoloff.   

Abstract

The D3 dopamine receptor, a D2-like receptor, is selectively expressed in the ventral striatum, particularly in the shell of nucleus accumbens and islands of Calleja, where it is found in medium sized substance P neurons. The latter co-express the D1 receptor whose interaction with the D3 receptor was studied by treating rats with selective agonists and antagonists. In agreement with the opposite cAMP response, they mediate in cultured neuroblastoma cells, the D1 and D3 receptors exerted opposite influences on c-fos expression in islands of Calleja. However, in agreement with the synergistic influence of cAMP on D3 receptor-mediated mitogenesis on the same cultured cells, D1 and D3 receptor stimulation in vivo synergistically enhanced preprotachykinin mRNA in the shell of accumbens. This indicates that the two receptor subtypes may affect neurons in either synergy or opposition according to the cell or signal generated. Levodopa-induced behavioral sensitization in hemiparkinsonian rats is another example of D1/D3 receptor interaction. Hence repeated levodopa administration induces the ectopic appearance of the D3 receptor in substance P/dynorphin, striatonigral neurons of the dorsal striatum. This induction is secondary to D1 receptor stimulation in neurons of the denervated side and fully accounts for the sensitization, i.e. the increased behavioral responsiveness to levodopa. During brain development, a similar process could operate to control the late appearance of the D3 receptor in D1-receptor bearing neurons of the ventral striatum at a time at which they start to be innervated by dopamine neurons. Finally, taking into account a variety of genetic, developmental, neuroimaging and pharmacological data, we postulate that imbalances between the levels of D1 and D3 receptors in the same neurons could be responsible for schizophrenic disorders. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9651537     DOI: 10.1016/s0165-0173(97)00046-5

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  34 in total

1.  Dopamine D1 and D3 receptors are differentially involved in cue-elicited cocaine seeking.

Authors:  Liping Chen; Ming Xu
Journal:  J Neurochem       Date:  2010-04-28       Impact factor: 5.372

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

3.  [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.

Authors:  Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

4.  Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats.

Authors:  Judit Laszy; István Laszlovszky; István Gyertyán
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

5.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

6.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay Riddle; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

7.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

8.  Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum.

Authors:  Daniel Marcellino; Sergi Ferré; Vicent Casadó; Antonio Cortés; Bernard Le Foll; Carmen Mazzola; Filippo Drago; Oliver Saur; Holger Stark; Aroa Soriano; Chanel Barnes; Steven R Goldberg; Carme Lluis; Kjell Fuxe; Rafael Franco
Journal:  J Biol Chem       Date:  2008-07-21       Impact factor: 5.157

9.  Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens.

Authors:  Daniel F Manvich; Alyssa K Petko; Rachel C Branco; Stephanie L Foster; Kirsten A Porter-Stransky; Kristen A Stout; Amy H Newman; Gary W Miller; Carlos A Paladini; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2019-03-16       Impact factor: 7.853

10.  Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists.

Authors:  Ji-Kyung Choi; Joseph B Mandeville; Y Iris Chen; Peter Grundt; Susanta K Sarkar; Amy H Newman; Bruce G Jenkins
Journal:  Psychopharmacology (Berl)       Date:  2010-07-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.